Research Reports | Market Assessment
September 2016

Hepatitis C Virus | Current Treatment | EU5 | 2016

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA authorizations of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), combined with Bristol-Myers Squibb’s Daklinza (daclatasvir) and AbbVie’s Viekirax +/- Exviera (ombitasvir/paritaprevir/ritonavir +/- dasabuvir), have ushered in the era of IFN-free therapy for chronic HCV and completely reshaped the HCV therapeutic market. Recent EMA approvals of Gilead’s Epclusa (sofosbuvir/velpatasvir) and Merck Sharpe & Dohme’s Zepatier (elbasvir/grazoprevir) provide additional IFN-free options for EU5 HCV patients. Taken together, currently approved regimens provide efficacious IFN-free options for most HCV genotypes in the EU5. This research focuses on current and anticipated use of all-oral HCV regimens, including IFN-free and remaining IFN-based regimens, by capturing patient- and market-share data, current prescribing trends, and anticipated changes in prescribing and treatment. We also evaluate physician-perceived drivers and limitations to the uptake of key brands and the effectiveness of these agents’ salesforces.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports